<DOC>
	<DOCNO>NCT02055014</DOCNO>
	<brief_summary>New effective non-surgical treatment need patient whose obesity type 2 diabetes ( T2DM ) respond current medical therapy . We propose randomise controlled trial Endobarrier , implantable intestinal device separate ingest food contact first 60cm intestine sit mimic clinical effect bariatric surgery ( improve metabolic control weight loss ) without continue use GLP-1 receptor agonist ( GLP-1RA ) Liraglutide 1.2mg v Liraglutide 1.8mg without device obese patient T2DM remain suboptimal glycaemic control despite current conventional diabetes treatment , NHS set . Seventy-two patient T2DM obesity ( HbA1c≥7.5 % , BMI≥35kg/m2 ) despite previous GLP-1RA therapy study 24 month randomise receive Endobarrier continue Liraglutide 1.2mg 12 month ; Endobarrier alone 12 month ; Liraglutide 1.8mg without Endobarrier . We investigate potential mechanism action time course part study repeat measure : 1. insulin resistance measure , gut peptide , bile acid ; 2. energy intake nutritional composition ; 3. liver fat store , 4. intestinal inflammation permeability measure . The data inform clinical use device development new treatment T2DM obesity .</brief_summary>
	<brief_title>Randomisation Endobarrier Alone Versus With Incretin Analogue SustainEd Diabesity ( REVISE-Diabesity )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>type 2 diabetes late HbA1c ≥7.5 % ( ≥58mmol/mol ) obesity late BMI ≥35 Kg/m2 ( ≥30 Kg/m2 South Asian origin ) liraglutide therapy least 6 month HbA1c weight trend data available stable weight HbA1c precede 3 month ( &lt; 3 Kg reduction weight &lt; 0.3 % reduction HbA1c ) &lt; 18 year age abnormal intestinal anatomy e.g . Crohn 's disease contraindication oesophagogastroduodenoscopy previous bariatric surgery bowel surgery active infection anticoagulation therapy discontinued/ coagulopathy INR &gt; 1.3 eGFR &lt; 30 know portal hypertension previous pancreatitis amylase &gt; 3 time upper limit normal uncontrolled cardiovascular disease lactate pregnant female patient take aspirin continue ( e.g . active ischaemic heart disease cerebrovascular disease ) excess anaesthetic risk identify anaesthetist investigator ( e.g . uncontrolled obstructive sleep apnoea )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Endobarrier</keyword>
	<keyword>Duodenal-jejunal bypass liner</keyword>
	<keyword>Glucagon-like peptide-1 receptor agonist</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Diabesity</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Obesity</keyword>
</DOC>